Patrick Auberger



  • 2015 : Prince Albert 1er de Monaco Prize of Cancerology from the Académie Nationale de Médecine, (ANM)
  • 2014 : Raymond Rosen Prize from the Fondation pour la Recherche Médicale (FRM)
  • 1995 : Joseph, Amalric Prize from the Ligue Nationale contre le Cancer (LNCC)
  • 2012-2015 : Bonus for Scientific Excellence INSERM


Patrick Auberger is the head of the team entitled « Myeloid malignancies and multiple myeloma : mechanisms, pathophysiology and new therapies » at the C3M.

He is an expert in the field of oncohematology and they focus their attention on blood and bone marrow cancers including chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS) and multiple myeloma (MM) and their resistance to conventional and targeted therapies.

In this context, they study the implication of apoptosis and autophagy in hematopoietic malignancies and the possibility to target degradation processes such as autophagy for a better management of blood and bone marrow cancers. Regarding CML, they contributed to a better characterization of the mechanisms of resistance to tyrosine kinase inhibitors, a targeted therapy that deeply transformed the prognosis of this hematopoietic malignancy. Noticeably, they identified reactivation of several tyrosine kinase downstream of p210bcr/abl, the protein responsible for CML.

Concerning MDS, they discovered new and original mechanisms of resistance to conventional chemotherapies implicating several important degration pathways such as autophagy, the proteasome and chaperone-mediated autophagy. They also developed new molecules targeting these pathaways that could lead to a better management of patients suffering MDS and acute myeloid leukemias. Finally, regarding MM we deciphered a novel mechanism of resistance to Bortezomib, one of the leading treatment for this disease. This resistance mechanism consists is due to the overexpression of the small heat shock HSPB8 that could be therapeutically exploited.